HHS draft policy does not intend to act against compounding six peptides that meet strict conditions

Tento záznam sa zobrazuje v angličtine, kým nebude aktualizovaný jeho preklad.

The US Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 while the FDA's 503A bulk substances list is developed through rulemaking, but only when every condition in the policy is met. Those conditions include using only the peptide form and route of administration the policy lists, one active ingredient per product, a patient-specific prescription, a raw ingredient made by an FDA-registered manufacturer following good manufacturing practice with a valid certificate of analysis (lab test report), and reporting serious adverse events to the FDA. The notice, published in the Federal Register on 30 October with written comments accepted for two weeks, says the policy is not binding and may be revisited if a safety signal or product quality issue arises. It does not approve these peptides or add them to the list, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.

Zdroje

  1. 01Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(otvorí zdroj na novej karte) Federal Register
  2. 02Draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(otvorí zdroj na novej karte) US Department of Health and Human Services
  3. 03HHS to allow compounders to make 6 unapproved peptides(otvorí zdroj na novej karte) BioPharma Dive
  4. 04HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending(otvorí zdroj na novej karte) Arnold & Porter

Dotknuté peptidy

  1. NeschválenéBPC-157Syntetický žalúdočný pentadekapeptid (výskumná chemikália)15 Zakázané WADA
  2. NeschválenéEpitalonSyntetický tetrapeptid epifýzy (kandidát na geroprotektor)4 Zakázané WADA
  3. NeschválenéKPVTripeptid odvodený od alfa-MSH (výskumná chemikália)3 Zakázané WADA
  4. NeschválenéMOTS-cPeptid odvodený z mitochondrií (výskumný peptid)16 Zakázané WADA
  5. Schválené indeSemaxAnalóg fragmentu ACTH(4-10) (neuropeptid odvodený od melanokortínov)7
  6. NeschválenéTB-500Fragment tymozínu beta-4 (výskumná chemikália)7 Zakázané WADA